Prescription drug · NDA AUTHORIZED GENERIC
Verapamil Hydrochloride NDC 62135-532
Verapamil hydrochloride 100 mg/1 · Capsule, Extended release · Oral · Chartwell RX, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 62135-532-30 | 6213505323062135053230 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62135-532-30)Marketed from Mar 30, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Verapamil Hydrochloride
- Generic name (nonproprietary)
- verapamil hydrochloride
- Active ingredients
- Verapamil hydrochloride — 100 mg/1
- Dosage form
- Capsule, Extended release
- Route
- Oral
- Labeler
- Chartwell RX, LLCNDC labeler code 62135
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 020943
- Marketing start
- Listing expires
- Other FDA classes
- Calcium Channel Antagonists (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
- Identifiers
- Product ID 62135-532_3131e786-8a0d-233f-e063-6294a90ac12bSPL ID 3131e786-8a0d-233f-e063-6294a90ac12bSPL set ID 18f6d349-8c5c-4443-ac65-16bf6619ecdcRxCUI 897584UNII V3888OEY5RUPC 0362135532307
- Pharmacologic class
- Calcium Channel Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N462135053230followed by a unit qualifier and the quantityPackage 62135-0532-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Verapamil Hydrochloride Extended-release Capsules (PM) for oral use is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug …
Excerpt only. Read the full label for complete information.
About NDC 62135-532
- What is NDC 62135-532?
- 62135-532 is the product NDC for Verapamil Hydrochloride, Verapamil hydrochloride 100 mg/1 capsule, extended release, listed with the FDA by Chartwell RX, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Verapamil Hydrochloride.
- What is the active ingredient?
- Verapamil hydrochloride.
- Who is the labeler?
- Chartwell RX, LLC, NDC labeler code 62135. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Verapamil Hydrochloride?
- 131 other product NDCs are listed under this name. See all Verapamil Hydrochloride NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Verapamil Hydrochloride products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Verapamil hydrochloride | Verapamil hydrochloride 120 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1953 | 70771-1953-0170771-1953-05 |
| Verapamil hydrochloride | Verapamil hydrochloride 180 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1954 | 70771-1954-0170771-1954-05 |
| Verapamil hydrochloride | Verapamil hydrochloride 240 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1955 | 70771-1955-0170771-1955-05 |
| Verapamil hydrochloride | Verapamil hydrochloride 120 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-561 | 68382-0561-0168382-0561-05 |
| Verapamil hydrochloride | Verapamil hydrochloride 180 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-562 | 68382-0562-0168382-0562-05 |
| Verapamil hydrochloride | Verapamil hydrochloride 240 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-563 | 68382-0563-0168382-0563-05 |
| Verapamil Hydrochloride | Verapamil hydrochloride 120 mg/1 | Capsule, Extended releaseOral | Safecor Health LLC | 48433-145 | 48433-0145-20 |
| Verapamil Hydrochloride | Verapamil hydrochloride 180 mg/1 | TabletOral | REMEDYREPACK INC. | 70518-4513 | 70518-4513-00 |
| Verapamil Hydrochloride | Verapamil hydrochloride 2.5 mg/mL | Injection, SolutionIntravenous | REMEDYREPACK INC. | 70518-4453 | 70518-4453-00 |
| Verapamil Hydrochloride | Verapamil hydrochloride 2.5 mg/mL | Injection, SolutionIntravenous | Caplin Steriles Limited | 65145-114 | 65145-0114-05 |
Other NDCs under NDA 020943
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Verapamil Hydrochloride | Verapamil hydrochloride 100 mg/1 | Capsule, Extended releaseOral | Wilshire Pharmaceuticals, Inc. | 52536-485 |
| Verapamil Hydrochloride | Verapamil hydrochloride 200 mg/1 | Capsule, Extended releaseOral | Wilshire Pharmaceuticals, Inc. | 52536-486 |
| Verapamil Hydrochloride | Verapamil hydrochloride 300 mg/1 | Capsule, Extended releaseOral | Wilshire Pharmaceuticals, Inc. | 52536-487 |